Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations

Summary Patient-specific induced pluripotent stem cells (iPSCs) derived from somatic cells provide a unique tool for the study of human disease, as well as a promising source for cell replacement therapies. One crucial limitation has been the inability to perform experiments under genetically defined conditions. This is particularly relevant for late age onset disorders in which in vitro phenotypes are predicted to be subtle and susceptible to significant effects of genetic background variations. By combining zinc finger nuclease (ZFN)-mediated genome editing and iPSC technology, we provide a generally applicable solution to this problem, generating sets of isogenic disease and control human pluripotent stem cells that differ exclusively at either of two susceptibility variants for Parkinson's disease by modifying the underlying point mutations in the α-synuclein gene. The robust capability to genetically correct disease-causing point mutations in patient-derived hiPSCs represents significant progress for basic biomedical research and an advance toward hiPSC-based cell replacement therapies.

[1]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[2]  Hynek Wichterle,et al.  Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.

[3]  Jac A. Nickoloff,et al.  Gene Conversion Tracts from Double-Strand Break Repair in Mammalian Cells , 1998, Molecular and Cellular Biology.

[4]  Ludovic Vallier,et al.  Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. , 2010, The Journal of clinical investigation.

[5]  A. Viale,et al.  Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs , 2009, Nature.

[6]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[7]  R. Jaenisch,et al.  Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases , 2009, Nature Biotechnology.

[8]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[9]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[10]  Fred H. Gage,et al.  Modelling schizophrenia using human induced pluripotent stem cells , 2011, Nature.

[11]  Thuy D Vo,et al.  Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures , 2011, Nature Methods.

[12]  Julie V. Harness,et al.  Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. , 2011, Cell stem cell.

[13]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[14]  Jennifer A. Erwin,et al.  Derivation of Pre-X Inactivation Human Embryonic Stem Cells under Physiological Oxygen Concentrations , 2010, Cell.

[15]  Adam James Waite,et al.  An improved zinc-finger nuclease architecture for highly specific genome editing , 2007, Nature Biotechnology.

[16]  Krishanu Saha,et al.  Technical challenges in using human induced pluripotent stem cells to model disease. , 2009, Cell stem cell.

[17]  E. Rebar,et al.  Genome editing with engineered zinc finger nucleases , 2010, Nature Reviews Genetics.

[18]  Christine Richardson,et al.  Coupled Homologous and Nonhomologous Repair of a Double-Strand Break Preserves Genomic Integrity in Mammalian Cells , 2000, Molecular and Cellular Biology.

[19]  Terry Speed,et al.  Normalization of cDNA microarray data. , 2003, Methods.

[20]  R. Lahesmaa,et al.  High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity , 2010, Nature Biotechnology.

[21]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[22]  Ted M. Dawson,et al.  Genetic Animal Models of Parkinson's Disease , 2010, Neuron.

[23]  Hynek Wichterle,et al.  A functionally characterized test set of human induced pluripotent stem cells , 2011, Nature Biotechnology.

[24]  George Q. Daley,et al.  Prospects for Stem Cell-Based Therapy , 2008, Cell.

[25]  Hidetoshi Shimodaira,et al.  Pvclust: an R package for assessing the uncertainty in hierarchical clustering , 2006, Bioinform..

[26]  L. Golbe,et al.  Clinical genetic analysis of Parkinson's disease in the contursi kindred , 1996, Annals of neurology.

[27]  T. Deerinck,et al.  Investigating synapse formation and function using human pluripotent stem cell-derived neurons , 2011, Proceedings of the National Academy of Sciences.

[28]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[29]  Joseph K. Pickrell,et al.  Understanding mechanisms underlying human gene expression variation with RNA sequencing , 2010, Nature.

[30]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[31]  C. Lengner,et al.  Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. , 2008, Cell stem cell.

[32]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[33]  T. Hocking,et al.  Heritable Targeted Gene Disruption in Zebrafish Using Designed Zinc Finger Nucleases , 2008, Nature Biotechnology.

[34]  Aj Lees,et al.  Parkinson's disease (vol 373, pg 2055, 2009) , 2009 .

[35]  Riitta Lahesmaa,et al.  Copy number variation and selection during reprogramming to pluripotency , 2011, Nature.

[36]  G. Vogel.  Stem cells. Diseases in a dish take off. , 2010, Science.

[37]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[38]  S. Hughes,et al.  Altering the Genome by Homologous Recombination , 2010 .

[39]  R. Jaenisch,et al.  A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. , 2008, Cell stem cell.

[40]  Shondra M Pruett-Miller,et al.  High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases , 2011, Nature Methods.

[41]  Samira Kiani,et al.  Genetic engineering of human ES and iPS cells using TALE nucleases , 2011, Nature Biotechnology.

[42]  K. Schwarz,et al.  Targeted chromosomal gene modification in human cells by single-stranded oligodeoxynucleotides in the presence of a DNA double-strand break. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  J. Schulz.  Update on the pathogenesis of Parkinson’s disease , 2008, Journal of Neurology.

[44]  K. Schwarz,et al.  Zinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modifications. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  Marius Wernig,et al.  Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.

[46]  Fred H. Gage,et al.  A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells , 2010, Cell.

[47]  A. Dernburg,et al.  Identification of Chromosome Sequence Motifs That Mediate Meiotic Pairing and Synapsis in C. elegans , 2009, Nature Cell Biology.

[48]  R. Guigó,et al.  Transcriptome genetics using second generation sequencing in a Caucasian population , 2010, Nature.

[49]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[50]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[51]  E. Kirkness,et al.  Somatic coding mutations in human induced pluripotent stem cells , 2011, Nature.

[52]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[53]  G. Jones,et al.  Establishment, maintenance, and cloning of human dermal fibroblasts. , 1997, Methods in molecular biology.

[54]  Michael J. Ziller,et al.  Reference Maps of Human ES and iPS Cell Variation Enable High-Throughput Characterization of Pluripotent Cell Lines , 2011, Cell.

[55]  K. Summers.  Relationship between genotype and phenotype in monogenic diseases: Relevance to polygenic diseases , 1996, Human mutation.

[56]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[57]  Ryan Mills,et al.  Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants , 2011, Nature Biotechnology.

[58]  S. Rafii,et al.  Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions , 2010, Cell.

[59]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[60]  Prashant Mali,et al.  Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. , 2009, Cell stem cell.